Lomustine

Generic Name: Lomustine

Brand Names: Ceenu, Gleostine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₆ClN_₃O_₂

CAS Number: 13010-47-4

Unique Ingredient Identifier: 7BRF0Z81KG

Background: An alkylating agent of value against both hematologic malignancies and solid tumors.

Indication: For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.

Associated Conditions: Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma

Clinical Trials

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-01-13

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 29

Registration Number: NCT00276666

Locations: 🇮🇪
Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland
🇬🇧
Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom

and more 18 locations

Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2006-01-11

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 30

Registration Number: NCT00274911

Locations: 🇮🇪
Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Royal London Hospital, London, England, United Kingdom

and more 17 locations

Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

Phase 2

Completed

Conditions: Anaplastic Astrocytoma
Central Nervous System Neoplasm
Glioblastoma
Gliosarcoma
Spinal Cord Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lomustine
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2005-01-07

Last Posted Date: 2023-02-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 118

Registration Number: NCT00100802

Locations: 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States

Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

First Posted Date: 2004-07-26

Last Posted Date: 2012-03-20

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT00003929

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Phase 3

Completed

Conditions: Medulloblastoma

Interventions: Drug: Cisplatin
Radiation: Craniospinal Irradiation
Drug: Cyclophosphamide
Radiation: Involved-Field Radiation Therapy
Drug: Lomustine
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Vincristine Sulfate

First Posted Date: 2004-06-16

Last Posted Date: 2025-01-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 549

Registration Number: NCT00085735

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
Santa Barbara Cottage Hospital, Santa Barbara, California, United States
🇺🇸
Lee Memorial Health System, Fort Myers, Florida, United States

and more 194 locations

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: lomustine
Drug: procarbazine hydrochloride
Drug: vincristine sulfate
Radiation: low-LET photon therapy

First Posted Date: 2004-05-26

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 43

Registration Number: NCT00002806

Locations: 🇺🇸
CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States

and more 14 locations

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Phase 3

Completed

Conditions: Central Nervous System Tumors
Brain Tumors

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: lomustine
Drug: mesna
Drug: vincristine sulfate
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-05-24

Last Posted Date: 2014-08-01

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 421

Registration Number: NCT00002875

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 38 locations

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-05-21

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT00003101

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 4 locations

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Bone Marrow Suppression
Drug/Agent Toxicity by Tissue/Organ

Interventions: Procedure: filgrastim
Biological: gene therapy
Drug: lomustine
Drug: procarbazine hydrochloride
Drug: vincristine sulfate
Procedure: in vitro-treated peripheral blood stem cell transplantation

First Posted Date: 2004-04-28

Last Posted Date: 2015-03-25

Lead Sponsor: Indiana University

Target Recruit Count: 10

Registration Number: NCT00005796

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma

Phase 3

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-01-22

Last Posted Date: 2012-07-10

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 350

Registration Number: NCT00002840

Locations: 🇫🇷
CHU de la Timone, Marseille, France
🇫🇷
CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium

and more 37 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy